A Multicenter, Double-blind, Randomized Study to Assess the Efficacy and Safety of Denosumab Produced by Two Different Processes in Postmenopausal Women With Osteoporosis
Phase of Trial: Phase III
Latest Information Update: 18 Aug 2017
Price : $35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Registrational; Therapeutic Use
- Sponsors Amgen
- 31 Aug 2018 Biomarkers information updated
- 02 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 31 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.